Cargando…
Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115497/ https://www.ncbi.nlm.nih.gov/pubmed/17640780 http://dx.doi.org/10.1016/j.vaccine.2007.06.017 |
_version_ | 1783514110453874688 |
---|---|
author | Hu, Mary C. Jones, Taff Kenney, Richard T. Barnard, Dale L. Burt, David S. Lowell, George H. |
author_facet | Hu, Mary C. Jones, Taff Kenney, Richard T. Barnard, Dale L. Burt, David S. Lowell, George H. |
author_sort | Hu, Mary C. |
collection | PubMed |
description | The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice. |
format | Online Article Text |
id | pubmed-7115497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71154972020-04-02 Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice Hu, Mary C. Jones, Taff Kenney, Richard T. Barnard, Dale L. Burt, David S. Lowell, George H. Vaccine Article The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice. Elsevier Ltd. 2007-08-21 2007-06-29 /pmc/articles/PMC7115497/ /pubmed/17640780 http://dx.doi.org/10.1016/j.vaccine.2007.06.017 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hu, Mary C. Jones, Taff Kenney, Richard T. Barnard, Dale L. Burt, David S. Lowell, George H. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title | Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title_full | Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title_fullStr | Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title_full_unstemmed | Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title_short | Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
title_sort | intranasal protollin-formulated recombinant sars s-protein elicits respiratory and serum neutralizing antibodies and protection in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115497/ https://www.ncbi.nlm.nih.gov/pubmed/17640780 http://dx.doi.org/10.1016/j.vaccine.2007.06.017 |
work_keys_str_mv | AT humaryc intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice AT jonestaff intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice AT kenneyrichardt intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice AT barnarddalel intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice AT burtdavids intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice AT lowellgeorgeh intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice |